A Plasma Metabolomic Signature Involving Purine Metabolism in Human Optic Atrophy 1 (OPA1)-Related Disorders

Archive ouverte

Bocca, Cinzia | Nzoughet, Judith | Leruez, Stéphanie | Amati-Bonneau, Patrizia | Ferré, Marc | Kane, Mariame-Selma | Veyrat-Durebex, Charlotte | Chao de La Barca, Juan Manuel | Chevrollier, Arnaud | Homedan, Chadi | Verny, Christophe | Milea, Dan | Procaccio, Vincent | Simard, Gilles | Bonneau, Dominique | Lenaers, Guy | Reynier, Pascal

Edité par CCSD ; Association for Research in Vision and Ophthalmology -

International audience.

Purpose: Dominant optic atrophy (DOA; MIM [Mendelian Inheritance in Man] 165500), resulting in retinal ganglion cell degeneration, is mainly caused by mutations in the optic atrophy 1 (OPA1) gene, which encodes a dynamin guanosine triphosphate (GTP)ase involved in mitochondrial membrane processing. This work aimed at determining whether plasma from OPA1 pathogenic variant carriers displays a specific metabolic signature.

Methods: We applied a nontargeted clinical metabolomics pipeline based on ultra-high-pressure liquid chromatography coupled to high-resolution mass spectrometry (UHPLC-HRMS) allowing the exploration of 500 polar metabolites in plasma. We compared the plasma metabolic profiles of 25 patients with various OPA1 pathogenic variants and phenotypes to those of 20 healthy controls. Statistical analyses were performed using univariate and multivariate (principal component analysis [PCA], orthogonal partial least-squares discriminant analysis [OPLS-DA]) methods and a machine learning approach, the Biosigner algorithm.

Results: A robust and relevant predictive model characterizing OPA1 individuals was obtained, based on a complex panel of metabolites with altered concentrations. An impairment of the purine metabolism, including significant differences in xanthine, hypoxanthine, and inosine concentrations, was at the foreground of this signature. In addition, the signature was characterized by differences in urocanate, choline, phosphocholine, glycerate, 1-oleoyl-rac-glycerol, rac-glycerol-1-myristate, aspartate, glutamate, and cystine concentrations.

Conclusions: This first metabolic signature reported in the plasma of patient carrying OPA1 pathogenic variants highlights the unexpected involvement of purine metabolism in the pathophysiology of DOA.

Consulter en ligne

Suggestions

Du même auteur

The metabolomic signature of Leber's hereditary optic neuropathy reveals endoplasmic reticulum stress

Archive ouverte | Chao de La Barca, Juan Manuel | CCSD

International audience. Leber's hereditary optic neuropathy (MIM#535000), the commonest mitochondrial DNA-related disease, is caused by mutations affecting mitochondrial complex I. The clinical expression of the dis...

OPA1-related disorders: Diversity of clinical expression, modes of inheritance and pathophysiology

Archive ouverte | Chao de La Barca, Juan Manuel | CCSD

International audience. Mutations in the Optic Atrophy 1 gene (OPA1) were first identified in 2000 as the main cause of Dominant Optic Atrophy, a disease specifically affecting the retinal ganglion cells and the opt...

Nicotinamide Deficiency in Primary Open-Angle Glaucoma

Archive ouverte | Kouassi Nzoughet, Judith | CCSD

International audience

Chargement des enrichissements...